Squarepoint’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-625,034
| Closed | -$338K | – | 4927 |
|
|
2025
Q2 | $338K | Buy |
625,034
+614,233
| +5,687% | +$365K | ﹤0.01% | 3596 |
|
|
2025
Q1 | $7.08K | Sell |
10,801
-699,562
| -98% | -$741K | ﹤0.01% | 4465 |
|
|
2024
Q4 | $725K | Buy |
+710,363
| New | +$1.3M | ﹤0.01% | 3373 |
|
|
2024
Q1 | – | Sell |
-41,146
| Closed | -$22.4K | – | 4550 |
|
|
2023
Q4 | $22.4K | Buy |
+41,146
| New | +$19K | ﹤0.01% | 3908 |
|
|
2022
Q4 | – | Sell |
-42,077
| Closed | -$206K | – | 3554 |
|
|
2022
Q3 | $206K | Buy |
42,077
+26,686
| +173% | +$137K | ﹤0.01% | 2680 |
|
|
2022
Q2 | $64K | Sell |
15,391
-8,881
| -37% | -$38.4K | ﹤0.01% | 2685 |
|
|
2022
Q1 | $141K | Buy |
+24,272
| New | +$144K | ﹤0.01% | 2555 |
|
|
2021
Q3 | – | Sell |
-12,573
| Closed | -$150K | – | 3379 |
|
|
2021
Q2 | $150K | Sell |
12,573
-42,885
| -77% | -$486K | ﹤0.01% | 2929 |
|
|
2021
Q1 | $695K | Sell |
55,458
-20,020
| -27% | -$270K | ﹤0.01% | 1785 |
|
|
2020
Q4 | $1.18M | Buy |
75,478
+13,098
| +21% | +$153K | 0.01% | 1214 |
|
|
2020
Q3 | $589K | Buy |
+62,380
| New | +$675K | 0.01% | 1307 |
|
|
2020
Q2 | – | Sell |
-53,294
| Closed | -$339K | – | 2495 |
|
|
2020
Q1 | $339K | Sell |
53,294
-52,575
| -50% | -$390K | 0.01% | 1244 |
|
|
2019
Q4 | $886K | Sell |
105,869
-68,871
| -39% | -$633K | 0.01% | 1412 |
|
|
2019
Q3 | $1.58M | Buy |
174,740
+113,232
| +184% | +$1.27M | 0.01% | 957 |
|
|
2019
Q2 | $662K | Buy |
61,508
+24,363
| +66% | +$259K | 0.01% | 1504 |
|
|
2019
Q1 | $354K | Buy |
37,145
+17,469
| +89% | +$178K | ﹤0.01% | 1668 |
|
|
2018
Q4 | $226K | Sell |
19,676
-16,274
| -45% | -$202K | ﹤0.01% | 1641 |
|
|
2018
Q3 | $609K | Sell |
35,950
-27,400
| -43% | -$416K | 0.01% | 1221 |
|
|
2018
Q2 | $900K | Sell |
63,350
-57,211
| -47% | -$950K | 0.01% | 933 |
|
|
2018
Q1 | $2.29M | Buy |
120,561
+77,725
| +181% | +$1.66M | 0.04% | 521 |
|
|
2017
Q4 | $703K | Buy |
+42,836
| New | +$637K | 0.01% | 996 |
|
|
2017
Q1 | – | Sell |
-39,001
| Closed | -$119K | – | 1875 |
|
|
2016
Q4 | $119K | Buy |
+39,001
| New | +$142K | ﹤0.01% | 1592 |
|
|
2016
Q3 | – | Sell |
-15,300
| Closed | -$89K | – | 1235 |
|
|
2016
Q2 | $89K | Buy |
+15,300
| New | +$97.5K | 0.01% | 988 |
|
|
2016
Q1 | – | Sell |
-29,500
| Closed | -$269K | – | 1423 |
|
|
2015
Q4 | $269K | Buy |
+29,500
| New | +$227K | 0.03% | 852 |
|
Other funds holding SGMO
GCP
Squarepoint's SGMO Position: Q3 2025 in Review
Squarepoint sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 625,034 shares — an estimated $338K sold.
Squarepoint first reported a position in SGMO in Q4 2015 and held it in 24 quarters. The position peaked at $2.29M in Q1 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.
- Squarepoint reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 625,034 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $338K.
- Squarepoint first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 24 quarters.
- Squarepoint's SANGAMO THERAPEUTICS INC position peaked at $2.29M in Q1 2018.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.